Oral abstract
402 OUTCOMES FROM AN INTERNATIONAL MULTICENTRE REGISTRY OF PATIENTS WITH ACUTE GASTROINTESTINAL BLEEDING UNDERGOING ENDOSCOPIC TREATMENT WITH HEMOSPRAY

https://doi.org/10.1016/j.gie.2018.04.070Get rights and content

Introduction

Acute gastrointestinal bleeding can carry poor outcomes unless prompt endoscopic haemostasis is achieved. Hemospray is a novel proprietary mineral blend that forms a mechanical barrier over the bleeding site when applied endoscopically. The primary aim of this international prospective multicentre registry is to collect data on the outcomes of patients with AGIB after endoscopic application of Hemospray. Secondary outcomes of rebleeding, 30 day mortality, disease and procedure specific outcomes were collected.

Section snippets

Method

Data were collected prospectively (Jan 2016-Nov 2017) on the use of Hemospray in AGIB, from 11 centres across UK, France and Germany. The use of Hemospray was at the endoscopist’s discretion at the time of endoscopy. Hemospray application was either as mono therapy, as dual-therapy with standard haemostatic endoscopic techniques or as rescue therapy once standard methods had failed. Immediate haemostasis defined as observed cessation of bleeding within 5 minutes after the endoscopic application

Results

To date 228 cases have been recruited (166M and 62F). 202 patients (89%) achieved immediate haemostasis after endoscopic therapy with Hemospray. Equivalent haemostasis rates were seen in the Hemospray monotherapy (90%), combination therapy (89%) and rescue therapy (85%) groups. Peptic ulcer bleed (122/228=54%) was the most common pathology and forrest Ib (151/228=66%) the most common lesion type (Table 1). Mean pre-treatment Blatchford score BS was 11 for all cases. 26 patients did not achieve

Conclusion

Data from this international multi-centre registry show the largest worldwide dataset to date on endoscopic application of Hemospray in AGIB. High rate of immediate haemostasis (89%) and excellent safety profile noted. Forrest 1b lesions at baseline have a higher rate of unsuccessful haemostais and an increased risk of rebleeding after initial therapy. Patient’s with rebleeding and unsuccessful initial treatment had higher BS’s at baseline than those with successful treatment. The continual

References (0)

Cited by (0)

View full text